Skip to main content
SpringerLink
Log in

Neurotoxicology Emergencies

  • Chapter
  • First Online:
Emergency Neurology

  • 1367 Accesses

Abstract

Exposure to pharmaceutical, occupational, or environmental toxins may cause or increase the risk of certain neurological emergencies. Early identification of the exposure and the toxin can be instrumental in the diagnosis and management of toxin-induced neurological emergencies. This chapter reviews the toxins associated with hyperthermic syndromes, ischemic and hemorrhagic stroke, seizures and status epilepticus, weakness, and acute encephalopathy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Rusyniak DE, Sprague JE. Toxin-induced hyperthermic syndromes. Med Clin N Am. 2005;89(6):1277–96.

    Article  CAS  PubMed  Google Scholar 

  2. Sternbach H. The serotonin syndrome. Am J Psychiatr. 1991;148(6):705–13.

    Article  CAS  PubMed  Google Scholar 

  3. Oates JA, Sjoerdsma A. Neurologic effects of tryptophan in patients receiving a monoamine oxidase inhibitor. Neurology. 1960;10:1076–8.

    Article  CAS  PubMed  Google Scholar 

  4. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352(11):1112–20.

    Article  CAS  PubMed  Google Scholar 

  5. Mackay FJ, Dunn NR, Mann RD. Antidepressants and the serotonin syndrome in general practice. Br J Gen Pract. 1999;49(448):871–4.

    CAS  PubMed  PubMed Central  Google Scholar 

  6. Watson WA, Litovitz TL, Rodgers GC Jr, Klein-Schwartz W, Reid N, Youniss J, et al. 2004 annual report of the American Association of Poison Control Centers toxic exposure surveillance system. Am J Emerg Med. 2005;23(5):589–666.

    Article  PubMed  Google Scholar 

  7. Isbister GK, Bowe SJ, Dawson A, Whyte IM. Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol Clin Toxicol. 2004;42(3):277–85.

    Article  CAS  PubMed  Google Scholar 

  8. Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F. Serotonin syndrome: analysis of cases registered in the French pharmacovigilance database. J Clin Psychopharmacol. 2015;35(4):382–8.

    Article  CAS  PubMed  Google Scholar 

  9. Culbertson VL, Rahman SE, Bosen GC, Caylor ML, Xu D. Use of a bioinformatics-based toxicity scoring system to assess serotonin burden and predict population-level adverse drug events from concomitant serotonergic drug therapy. Pharmacotherapy. 2019;39(2):171–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Pilgrim JL, Gerostamoulos D, Drummer OH. Deaths involving serotonergic drugs. Forensic Sci Int. 2010;198(1–3):110–7.

    Article  CAS  PubMed  Google Scholar 

  11. Azmitia EC, Whitaker-Azmitia PM. Awakening the sleeping giant: anatomy and plasticity of the brain serotonergic system. J Clin Psychiatry. 1991;52(Suppl):4–16.

    PubMed  Google Scholar 

  12. Cooper JR, Bloom FE, Roth RH. Serotonin, histamine, and adenosine. The biochemical basis of neuropharmacology. 8th ed. Oxford: Oxford University Press; 2003. p. 271–320.

    Google Scholar 

  13. Prosser JM, Nelson LS. The toxicology of bath salts: a review of synthetic cathinones. J Med Toxicol. 2012;8(1):33–42.

    Article  PubMed  Google Scholar 

  14. Schep LJ, Slaughter RJ, Vale JA, Beasley DM, Gee P. The clinical toxicology of the designer “party pills” benzylpiperazine and trifluoromethylphenylpiperazine. Clin Toxicol (Philadelphia, Pa). 2011;49(3):131–41.

    Google Scholar 

  15. Tang MH, Ching CK, Tsui MS, Chu FK, Mak TW. Two cases of severe intoxication associated with analytically confirmed use of the novel psychoactive substances 25B-NBOMe and 25C-NBOMe. Clin Toxicol (Philadelphia, Pa). 2014;52(5):561–5.

    Google Scholar 

  16. Evans RW, Tepper SJ, Shapiro RE, Sun-Edelstein C, Tietjen GE. The FDA alert on serotonin syndrome with use of triptans combined with selective serotonin reuptake inhibitors or selective serotonin-norepinephrine reuptake inhibitors: American Headache Society position paper. Headache. 2010;50(6):1089–99.

    Article  PubMed  Google Scholar 

  17. Acker EC, Sinclair EA, Beardsley AL, Ahmed SS, Froberg BA. Acute vilazodone toxicity in a pediatric patient. J Emerg Med. 2015;49(3):284–6.

    Article  PubMed  Google Scholar 

  18. Heise CW, Malashock H, Brooks DE. A review of vilazodone exposures with focus on serotonin syndrome effects. Clin Toxicol (Philadelphia, Pa). 2017;55(9):1004–7.

    Google Scholar 

  19. Thorpe EL, Pizon AF, Lynch MJ, Boyer J. Bupropion induced serotonin syndrome: a case report. J Med Toxicol. 2010;6(2):168–71.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Moss MJ, Hendrickson RG. Serotonin toxicity: associated agents and clinical characteristics. J Clin Psychopharmacol. 2019;39(6):628–33.

    Article  CAS  PubMed  Google Scholar 

  21. Solhaug V, Molden E. Individual variability in clinical effect and tolerability of opioid analgesics – importance of drug interactions and pharmacogenetics. Scand J Pain. 2017;17:193–200.

    Article  PubMed  Google Scholar 

  22. Tashakori A, Afshari R. Tramadol overdose as a cause of serotonin syndrome: a case series. Clin Toxicol (Philadelphia, Pa). 2010;48(4):337–41.

    Google Scholar 

  23. Park J, Chung ME. Botulinum toxin for central neuropathic pain. Toxins. 2018;10(6):224.

    Google Scholar 

  24. Ryan NM, Isbister GK. Tramadol overdose causes seizures and respiratory depression but serotonin toxicity appears unlikely. Clin Toxicol (Philadelphia, Pa). 2015;53(6):545–50.

    Google Scholar 

  25. Baldo BA, Rose MA. The anaesthetist, opioid analgesic drugs, and serotonin toxicity: a mechanistic and clinical review. Br J Anaesth. 2020;124(1):44–62.

    Article  CAS  PubMed  Google Scholar 

  26. Baldo BA. Opioid analgesic drugs and serotonin toxicity (syndrome): mechanisms, animal models, and links to clinical effects. Arch Toxicol. 2018;92(8):2457–73.

    Article  CAS  PubMed  Google Scholar 

  27. Chan BS, Becker T, Chiew AL, Abdalla AM, Robertson TA, Liu X, et al. Vasoplegic shock treated with methylene blue complicated by severe serotonin syndrome. J Med Toxicol. 2018;14(1):100–3.

    Article  PubMed  Google Scholar 

  28. Francescangeli J, Vaida S, Bonavia AS. Perioperative diagnosis and treatment of serotonin syndrome following administration of methylene blue. Am J Case Rep. 2016;17:347–51.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Hencken L, To L, Ly N, Morgan JA. Serotonin syndrome following methylene blue administration for vasoplegic syndrome. J Card Surg. 2016;31(4):208–10.

    Article  PubMed  Google Scholar 

  30. Martino EA, Winterton D, Nardelli P, Pasin L, Calabro MG, Bove T, et al. The blue coma: the role of methylene blue in unexplained coma after cardiac surgery. J Cardiothorac Vasc Anesth. 2016;30(2):423–7.

    Article  CAS  PubMed  Google Scholar 

  31. Ng BK, Cameron AJ. The role of methylene blue in serotonin syndrome: a systematic review. Psychosomatics. 2010;51(3):194–200.

    Article  PubMed  Google Scholar 

  32. Oz M, Isaev D, Lorke DE, Hasan M, Petroianu G, Shippenberg TS. Methylene blue inhibits function of the 5-HT transporter. Br J Pharmacol. 2012;166(1):168–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Smith CJ, Wang D, Sgambelluri A, Kramer RS, Gagnon DJ. Serotonin syndrome following methylene blue administration during cardiothoracic surgery. J Pharm Pract. 2015;28(2):207–11.

    Article  PubMed  Google Scholar 

  34. Snyder M, Gangadhara S, Brohl AS, Ludlow S, Nanjappa S. Serotonin syndrome complicating treatment of ifosfamide neurotoxicity with methylene blue. Cancer Control J Moffitt Cancer Center. 2017;24(5):1073274817729070.

    Google Scholar 

  35. Stanford SC, Stanford BJ, Gillman PK. Risk of severe serotonin toxicity following co-administration of methylene blue and serotonin reuptake inhibitors: an update on a case report of post-operative delirium. J Psychopharmacol (Oxford, England). 2010;24(10):1433–8.

    Google Scholar 

  36. Top WM, Gillman PK, de Langen CJ, Kooy A. Fatal methylene blue associated serotonin toxicity. Neth J Med. 2014;72(3):179–81.

    CAS  PubMed  Google Scholar 

  37. Zuschlag ZD, Warren MW, Schultz KS. Serotonin toxicity and urinary analgesics: a case report and systematic literature review of methylene blue-induced serotonin syndrome. Psychosomatics. 2018;59(6):539–46.

    Article  PubMed  Google Scholar 

  38. Frykberg RG, Gordon S, Tierney E, Banks J. Linezolid-associated serotonin syndrome. A report of two cases. J Am Podiatr Med Assoc. 2015;105(3):244–8.

    Article  PubMed  Google Scholar 

  39. Karkow DC, Kauer JF, Ernst EJ. Incidence of serotonin syndrome with combined use of linezolid and serotonin reuptake inhibitors compared with linezolid monotherapy. J Clin Psychopharmacol. 2017;37(5):518–23.

    Article  CAS  PubMed  Google Scholar 

  40. Ramsey TD, Lau TT, Ensom MH. Serotonergic and adrenergic drug interactions associated with linezolid: a critical review and practical management approach. Ann Pharmacother. 2013;47(4):543–60.

    Article  PubMed  Google Scholar 

  41. Woytowish MR, Maynor LM. Clinical relevance of linezolid-associated serotonin toxicity. Ann Pharmacother. 2013;47(3):388–97.

    Article  PubMed  Google Scholar 

  42. Koury KM, Tsui B, Gulur P. Incidence of serotonin syndrome in patients treated with fentanyl on serotonergic agents. Pain Physician. 2015;18(1):E27–30.

    PubMed  Google Scholar 

  43. Robles LA. Serotonin syndrome induced by fentanyl in a child: case report. Clin Neuropharmacol. 2015;38(5):206–8.

    Article  PubMed  Google Scholar 

  44. Pedavally S, Fugate JE, Rabinstein AA. Serotonin syndrome in the intensive care unit: clinical presentations and precipitating medications. Neurocrit Care. 2014;21(1):108–13.

    Article  CAS  PubMed  Google Scholar 

  45. Gillman PK. The serotonin syndrome and its treatment. J Psychopharmacol. 1999;13(1):100–9.

    Article  CAS  PubMed  Google Scholar 

  46. Slettedal JK, Nilssen DO, Magelssen M, Loberg EM, Maehlen J. Brain pathology in fatal serotonin syndrome: presentation of two cases. Neuropathology. 2011;31(3):265–70.

    Article  PubMed  Google Scholar 

  47. Radomski J, Dursun S, Reveley M, Kutcher S. An exploratory approach to the serotonin syndrome: an update of clinical phenomenology and revised diagnostic criteria. Med Hypotheses. 2000;55(3):218–24.

    Article  CAS  PubMed  Google Scholar 

  48. Dunkley EJC, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The hunter serotonin toxicity criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96(9):635–42.

    Article  CAS  PubMed  Google Scholar 

  49. Werneke U, Jamshidi F, Taylor DM, Ott M. Conundrums in neurology: diagnosing serotonin syndrome – a meta-analysis of cases. BMC Neurol. 2016;16:97.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Hegerl U, Bottlender R, Gallinat J, Kuss HJ, Ackenheil M, Moller HJ. The serotonin syndrome scale: first results on validity. Eur Arch Psychiatry Clin Neurosci. 1998;248(2):96–103.

    Article  CAS  PubMed  Google Scholar 

  51. Hilton SE, Maradit H, Moller HJ. Serotonin syndrome and drug combinations: focus on MAOI and RIMA. Eur Arch Psychiatry Clin Neurosci. 1997;247(3):113–9.

    Article  CAS  PubMed  Google Scholar 

  52. Baloh RW, Dietz J, Spooner JW. Myoclonus and ocular oscillations induced by L-tryptophan. Ann Neurol. 1982;11(1):95–7.

    Article  CAS  PubMed  Google Scholar 

  53. Mills KC. Serotonin syndrome. A clinical update. Crit Care Clin. 1997;13(4):763–83.

    Article  CAS  PubMed  Google Scholar 

  54. Perry PJ, Wilborn CA. Serotonin syndrome vs neuroleptic malignant syndrome: a contrast of causes, diagnoses, and management. Ann Clin Psychiatry. 2012;24(2):155–62.

    PubMed  Google Scholar 

  55. Nisijima K. Abnormal monoamine metabolism in cerebrospinal fluid in a case of serotonin syndrome. J Clin Psychopharmacol. 2000;20(1):107–8.

    Article  CAS  PubMed  Google Scholar 

  56. Nisijima K, Nibuya M, Sugiyama H. Abnormal CSF monoamine metabolism in serotonin syndrome. J Clin Psychopharmacol. 2003;23(5):528–31.

    Article  PubMed  Google Scholar 

  57. Stewart RM, Campbell A, Sperk G, Baldessarini RJ. Receptor mechanisms in increased sensitivity to serotonin agonists after dihydroxytryptamine shown by electronic monitoring of muscle twitches in the rat. Psychopharmacology. 1979;60(3):281–9.

    Article  CAS  PubMed  Google Scholar 

  58. Gerson SC, Baldessarini RJ. Motor effects of serotonin in the central nervous system. Life Sci. 1980;27(16):1435–51.

    Article  CAS  PubMed  Google Scholar 

  59. Graudins A, Stearman A, Chan B. Treatment of the serotonin syndrome with cyproheptadine. J Emerg Med. 1998;16(4):615–9.

    Article  CAS  PubMed  Google Scholar 

  60. McDaniel WW. Serotonin syndrome: early management with cyproheptadine. Ann Pharmacother. 2001;35(7–8):870–3.

    Article  CAS  PubMed  Google Scholar 

  61. Lappin RI, Auchincloss EL. Treatment of the serotonin syndrome with cyproheptadine. N Engl J Med. 1994;331(15):1021–2.

    Article  CAS  PubMed  Google Scholar 

  62. Nguyen H, Pan A, Smollin C, Cantrell LF, Kearney T. An 11-year retrospective review of cyproheptadine use in serotonin syndrome cases reported to the California Poison Control System. J Clin Pharm Ther. 2019;44(2):327–34.

    Article  CAS  PubMed  Google Scholar 

  63. Chu FK. Review of the epidemiology and characteristics of intentional cyproheptadine overdose in Hong Kong. Clin Toxicol (Philadelphia, Pa). 2011;49(7):681–3.

    Google Scholar 

  64. Racz R, Soldatos TG, Jackson D, Burkhart K. Association between serotonin syndrome and second-generation antipsychotics via pharmacological target-adverse event analysis. Clin Transl Sci. 2018;11(3):322–9.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Delay J, Pichot P, Lemperiere T, Elissalde B, Peigne F. A non-phenothiazine and non-reserpine major neuroleptic, haloperidol, in the treatment of psychoses. Ann Med Psychol. 1960;118(1):145–52.

    Google Scholar 

  66. Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin N Am. 1993;77(1):185–202.

    Article  CAS  PubMed  Google Scholar 

  67. Stubner S, Rustenbeck E, Grohmann R, Wagner G, Engel R, Neundorfer G, et al. Severe and uncommon involuntary movement disorders due to psychotropic drugs. Pharmacopsychiatry. 2004;37(Suppl 1):S54–64.

    PubMed  Google Scholar 

  68. Spivak B, Maline DI, Kozyrev VN, Mester R, Neduva SA, Ravilov RS, et al. Frequency of neuroleptic malignant syndrome in a large psychiatric hospital in Moscow. Eur Psychiatry. 2000;15(5):330–3.

    Article  CAS  PubMed  Google Scholar 

  69. Addonizio G, Susman VL, Roth SD. Symptoms of neuroleptic malignant syndrome in 82 consecutive inpatients. Am J Psychiatr. 1986;143(12):1587–90.

    Article  CAS  PubMed  Google Scholar 

  70. Deng MZ, Chen GQ, Phillips MR. Neuroleptic malignant syndrome in 12 of 9,792 Chinese inpatients exposed to neuroleptics: a prospective study. Am J Psychiatr. 1990;147(9):1149–55.

    Article  CAS  PubMed  Google Scholar 

  71. Keck PE Jr, Pope HG Jr, McElroy SL. Frequency and presentation of neuroleptic malignant syndrome: a prospective study. Am J Psychiatr. 1987;144(10):1344–6.

    Article  PubMed  Google Scholar 

  72. Kimura G, Kadoyama K, Brown JB, Nakamura T, Miki I, Nisiguchi K, et al. Antipsychotics-associated serious adverse events in children: an analysis of the FAERS database. Int J Med Sci. 2015;12(2):135–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Ananth J, Parameswaran S, Gunatilake S, Burgoyne K, Sidhom T. Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry. 2004;65(4):464–70.

    Article  CAS  PubMed  Google Scholar 

  74. Anzai T, Takahashi K, Watanabe M. Adverse reaction reports of neuroleptic malignant syndrome induced by atypical antipsychotic agents in the Japanese Adverse Drug Event Report (JADER) database. Psychiatry Clin Neurosci. 2019;73(1):27–33.

    Article  CAS  PubMed  Google Scholar 

  75. Belvederi Murri M, Guaglianone A, Bugliani M, Calcagno P, Respino M, Serafini G, et al. Second-generation antipsychotics and neuroleptic malignant syndrome: systematic review and case report analysis. Drugs R&D. 2015;15(1):45–62.

    Article  CAS  Google Scholar 

  76. Breeden R, Ford H, Chrisman C, Mascioli C. Neuroleptic malignant syndrome secondary to metoclopramide use in an elderly gastroenterologic surgery patient. Gastroenterol Nursing. 2017;40(2):93–100.

    Article  Google Scholar 

  77. Lau Moon Lin M, Robinson PD, Flank J, Sung L, Dupuis LL. The safety of metoclopramide in children: a systematic review and meta-analysis. Drug Saf. 2016;39(7):675–87.

    Article  PubMed  Google Scholar 

  78. Lau Moon Lin M, Robinson PD, Flank J, Sung L, Dupuis LL. The safety of prochlorperazine in children: a systematic review and meta-analysis. Drug Saf. 2016;39(6):509–16.

    Article  PubMed  Google Scholar 

  79. Lertxundi U, Ruiz AI, Aspiazu MA, Domingo-Echaburu S, Garcia M, Aguirre C, et al. Adverse reactions to antipsychotics in Parkinson disease: an analysis of the Spanish pharmacovigilance database. Clin Neuropharmacol. 2015;38(3):69–84.

    Article  CAS  PubMed  Google Scholar 

  80. Guay DR. Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders. Am J Geriatr Pharmacother. 2010;8(4):331–73.

    Article  CAS  PubMed  Google Scholar 

  81. Bonnici A, Ruiner CE, St-Laurent L, Hornstein D. An interaction between levodopa and enteral nutrition resulting in neuroleptic malignant-like syndrome and prolonged ICU stay. Ann Pharmacother. 2010;44(9):1504–7.

    Article  PubMed  Google Scholar 

  82. Fiore S, Persichino L, Anticoli S, De Pandis MF. A neuroleptic malignant-like syndrome (NMLS) in a patient with Parkinson’s disease resolved with rotigotine: a case report. Acta Biomed: Atenei Parmensis. 2014;85(3):281–4.

    Google Scholar 

  83. Fryml LD, Williams KR, Pelic CG, Fox J, Sahlem G, Robert S, et al. The role of amantadine withdrawal in 3 cases of treatment-refractory altered mental status. J Psychiatr Pract. 2017;23(3):191–9.

    Article  PubMed  Google Scholar 

  84. Whitman CB, Ablordeppey E, Taylor B. Levodopa withdrawal presenting as fever in a critically ill patient receiving concomitant enteral nutrition. J Pharm Pract. 2016;29(6):574–8.

    Article  PubMed  Google Scholar 

  85. Nakamura M, Yasunaga H, Miyata H, Shimada T, Horiguchi H, Matsuda S. Mortality of neuroleptic malignant syndrome induced by typical and atypical antipsychotic drugs: a propensity-matched analysis from the Japanese Diagnosis Procedure Combination database. J Clin Psychiatry. 2012;73(4):427–30.

    Article  PubMed  Google Scholar 

  86. Gurrera RJ. A systematic review of sex and age factors in neuroleptic malignant syndrome diagnosis frequency. Acta Psychiatr Scand. 2017;135(5):398–408.

    Article  PubMed  Google Scholar 

  87. Nielsen RE, Wallenstein Jensen SO, Nielsen J. Neuroleptic malignant syndrome-an 11-year longitudinal case-control study. Can J Psychiatry. 2012;57(8):512–8.

    Article  PubMed  Google Scholar 

  88. Su YP, Chang CK, Hayes RD, Harrison S, Lee W, Broadbent M, et al. Retrospective chart review on exposure to psychotropic medications associated with neuroleptic malignant syndrome. Acta Psychiatr Scand. 2014;130(1):52–60.

    Article  CAS  PubMed  Google Scholar 

  89. Keck PE Jr, Pope HG Jr, McElroy SL. Declining frequency of neuroleptic malignant syndrome in a hospital population. Am J Psychiatr. 1991;148(7):880–2.

    Article  PubMed  Google Scholar 

  90. Viejo LF, Morales V, Punal P, Perez JL, Sancho RA. Risk factors in neuroleptic malignant syndrome. A case-control study. Acta Psychiatr Scand. 2003;107(1):45–9.

    Article  CAS  PubMed  Google Scholar 

  91. Sheehan R, Horsfall L, Strydom A, Osborn D, Walters K, Hassiotis A. Movement side effects of antipsychotic drugs in adults with and without intellectual disability: UK population-based cohort study. BMJ Open. 2017;7(8):e017406.

    Article  PubMed  PubMed Central  Google Scholar 

  92. Berardi D, Amore M, Keck PE Jr, Troia M, Dell'Atti M. Clinical and pharmacologic risk factors for neuroleptic malignant syndrome: a case-control study. Biol Psychiatry. 1998;44(8):748–54.

    Article  CAS  PubMed  Google Scholar 

  93. Sachdev P, Mason C, Hadzi-Pavlovic D. Case-control study of neuroleptic malignant syndrome. Am J Psychiatr. 1997;154(8):1156–8.

    Article  CAS  PubMed  Google Scholar 

  94. Ciranni MA, Kearney TE, Olson KR. Comparing acute toxicity of first- and second-generation antipsychotic drugs: a 10-year, retrospective cohort study. J Clin Psychiatry. 2009;70(1):122–9.

    Article  CAS  PubMed  Google Scholar 

  95. Nisijima K, Ishiguro T. Cerebrospinal fluid levels of monoamine metabolites and gamma-aminobutyric acid in neuroleptic malignant syndrome. J Psychiatr Res. 1995;29(3):233–44.

    Article  CAS  PubMed  Google Scholar 

  96. Serrano-Duenas M. Neuroleptic malignant syndrome-like, or--dopaminergic malignant syndrome--due to levodopa therapy withdrawal. Clinical features in 11 patients. Parkinsonism Relat Disord. 2003;9(3):175–8.

    Article  PubMed  Google Scholar 

  97. Gordon PH, Frucht SJ. Neuroleptic malignant syndrome in advanced Parkinson’s disease. Mov Disord. 2001;16(5):960–2.

    Article  CAS  PubMed  Google Scholar 

  98. Nisijima K, Shioda K, Iwamura T. Neuroleptic malignant syndrome and serotonin syndrome. Prog Brain Res. 2007;162:81–104.

    Article  CAS  PubMed  Google Scholar 

  99. Gurrera RJ. Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome. Am J Psychiatr. 1999;156(2):169–80.

    Article  CAS  PubMed  Google Scholar 

  100. Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatr. 1985;142(10):1137–45.

    Article  CAS  PubMed  Google Scholar 

  101. Karamustafalioglu N, Kalelioglu T, Celikel G, Genc A, Emul M. Clinical utility of neutrophil-lymphocyte ratio in the diagnosis of neuroleptic malignant syndrome. Nord J Psychiatry. 2019;73(4–5):288–92.

    Article  PubMed  Google Scholar 

  102. Gurrera RJ, Mortillaro G, Velamoor V, Caroff SN. A validation study of the international consensus diagnostic criteria for neuroleptic malignant syndrome. J Clin Psychopharmacol. 2017;37(1):67–71.

    Article  PubMed  Google Scholar 

  103. Gurrera RJ, Caroff SN, Cohen A, Carroll BT, DeRoos F, Francis A, et al. An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method. J Clin Psychiatry. 2011;72(9):1222–8.

    Article  PubMed  Google Scholar 

  104. Caroff SN, Mann SC. Neuroleptic malignant syndrome. Psychopharmacol Bull. 1988;24(1):25–9.

    CAS  PubMed  Google Scholar 

  105. Modi S, Dharaiya D, Schultz L, Varelas P. Neuroleptic malignant syndrome: complications, outcomes, and mortality. Neurocrit Care. 2016;24(1):97–103.

    Article  PubMed  Google Scholar 

  106. Sachdev PS. A rating scale for neuroleptic malignant syndrome. Psychiatry Res. 2005;135(3):249–56.

    Article  PubMed  Google Scholar 

  107. Yacoub A, Francis A. Neuroleptic malignant syndrome induced by atypical neuroleptics and responsive to lorazepam. Neuropsychiatr Dis Treat. 2006;(2):235–40.

    Google Scholar 

  108. Pelonero AL, Levenson JL, Pandurangi AK. Neuroleptic malignant syndrome: a review. Psychiatr Serv. 1998;49(9):1163–72.

    Article  CAS  PubMed  Google Scholar 

  109. Strawn JR, Keck PE Jr, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatr. 2007;164(6):870–6.

    Article  PubMed  Google Scholar 

  110. Ghaziuddin N, Hendriks M, Patel P, Wachtel LE, Dhossche DM. Neuroleptic malignant syndrome/malignant catatonia in child psychiatry: literature review and a case series. J Child Adolesc Psychopharmacol. 2017;27(4):359–65.

    Article  PubMed  Google Scholar 

  111. Luchini F, Lattanzi L, Bartolommei N, Cosentino L, Litta A, Kansky C, et al. Catatonia and neuroleptic malignant syndrome: two disorders on a same spectrum? Four case reports. J Nerv Ment Dis. 2013;201(1):36–42.

    Article  PubMed  Google Scholar 

  112. Lang FU, Lang S, Becker T, Jager M. Neuroleptic malignant syndrome or catatonia? Trying to solve the catatonic dilemma. Psychopharmacology. 2015;232(1):1–5.

    Article  CAS  PubMed  Google Scholar 

  113. Nagamine M, Yoshino A, Sakurai Y, Sanga M, Takahashi R, Nomura S. Exacerbating factors in neuroleptic malignant syndrome: comparisons between cases with death, sequelae, and full recovery. J Clin Psychopharmacol. 2005;25(5):499–501.

    Article  PubMed  Google Scholar 

  114. Caroff SN, Mann SC, Keck PE Jr. Specific treatment of the neuroleptic malignant syndrome. Biol Psychiatry. 1998;44(6):378–81.

    CAS  PubMed  Google Scholar 

  115. Krause T, Gerbershagen MU, Fiege M, Weisshorn R, Wappler F. Dantrolene--a review of its pharmacology, therapeutic use and new developments. Anaesthesia. 2004;59(4):364–73.

    Article  CAS  PubMed  Google Scholar 

  116. Sakkas P, Davis JM, Janicak PG, Wang ZY. Drug treatment of the neuroleptic malignant syndrome. Psychopharmacol Bull. 1991;27(3):381–4.

    CAS  PubMed  Google Scholar 

  117. Rosenberg MR, Green M. Neuroleptic malignant syndrome. Review of response to therapy. Arch Intern Med. 1989;149(9):1927–31.

    Article  CAS  PubMed  Google Scholar 

  118. van Rensburg R, Decloedt EH. An approach to the pharmacotherapy of neuroleptic malignant syndrome. Psychopharmacol Bull. 2019;49(1):84–91.

    PubMed  PubMed Central  Google Scholar 

  119. Schreiner NM, Windham S, Barker A. Atypical neuroleptic malignant syndrome: diagnosis and proposal for an expanded treatment algorithm: a case report. A A Case Rep. 2017;9(12):339–43.

    Article  PubMed  Google Scholar 

  120. Nisijima K, Noguti M, Ishiguro T. Intravenous injection of levodopa is more effective than dantrolene as therapy for neuroleptic malignant syndrome. Biol Psychiatry. 1997;41(8):913–4.

    Article  CAS  PubMed  Google Scholar 

  121. Avarello TP, Cottone S. Serotonin syndrome: a reported case. Neurol Sci. 2002;23(Suppl 2):S55–6.

    Article  PubMed  Google Scholar 

  122. Sandyk R. L-dopa induced “serotonin syndrome” in a parkinsonian patient on bromocriptine. J Clin Psychopharmacol. 1986;6(3):194–5.

    Article  CAS  PubMed  Google Scholar 

  123. Cheng P-L, Hung S-W, Lin L-W, Chong C-F, Lau C-I. Amantadine-induced serotonin syndrome in a patient with renal failure. Am J Emerg Med. 2008;26(1):112.e5–6.

    Google Scholar 

  124. Trollor JN, Sachdev PS. Electroconvulsive treatment of neuroleptic malignant syndrome: a review and report of cases. Aust N Z J Psychiatry. 1999;33:650–9.

    Article  CAS  PubMed  Google Scholar 

  125. Scheftner WAMD, Shulman RBMD. Treatment choice in neuroleptic malignant syndrome. Convuls Ther. 1992;8(4):267–79.

    PubMed  Google Scholar 

  126. Ruth-Sahd LA, Rodrigues D, Shreve E. Neuroleptic malignant syndrome: a case report. Nursing. 2020;50(4):32–8.

    Article  PubMed  Google Scholar 

  127. San Gabriel MC, Eddula-Changala B, Tan Y, Longshore CT. Electroconvulsive in a schizophrenic patient with neuroleptic malignant syndrome and rhabdomyolysis. J ECT. 2015;31(3):197–200.

    Article  PubMed  Google Scholar 

  128. Casamassima F, Lattanzi L, Perlis RH, Litta A, Fui E, Bonuccelli U, et al. Neuroleptic malignant syndrome: further lessons from a case report. Psychosomatics. 2010;51(4):349–54.

    Article  CAS  PubMed  Google Scholar 

  129. Chiou YJ, Lee Y, Lin CC, Huang TL. A case report of catatonia and neuroleptic malignant syndrome with multiple treatment modalities: short communication and literature review. Medicine. 2015;94(43):e1752.

    Article  PubMed  PubMed Central  Google Scholar 

  130. Hashim H, Zebun N, Alrukn SA, Al Madani AA. Drug resistant neuroleptic malignant syndrome and the role of electroconvulsive therapy. JPMA: J Pak Med Assoc. 2014;64(4):471–3.

    Google Scholar 

  131. Denborough MA, Forster JF, Lovell RR, Maplestone PA, Villiers JD. Anaesthetic deaths in a family. Br J Anaesth. 1962;34:395–6.

    Article  CAS  PubMed  Google Scholar 

  132. Dexter F, Epstein RH, Wachtel RE, Rosenberg H. Estimate of the relative risk of succinylcholine for triggering malignant hyperthermia. Anesth Analg. 2013;116(1):118–22.

    Article  CAS  PubMed  Google Scholar 

  133. Hopkins PM. Malignant hyperthermia: pharmacology of triggering. Br J Anaesth. 2011;107(1):48–56.

    Article  CAS  PubMed  Google Scholar 

  134. Larach MG, Klumpner TT, Brandom BW, Vaughn MT, Belani KG, Herlich A, et al. Succinylcholine use and dantrolene availability for malignant hyperthermia treatment: database analyses and systematic review. Anesthesiology. 2019;130(1):41–54.

    Article  CAS  PubMed  Google Scholar 

  135. Migita T, Mukaida K, Kobayashi M, Hamada H, Kawamoto M. The severity of sevoflurane-induced malignant hyperthermia. Acta Anaesthesiol Scand. 2012;56(3):351–6.

    Article  CAS  PubMed  Google Scholar 

  136. Riazi S, Larach MG, Hu C, Wijeysundera D, Massey C, Kraeva N. Malignant hyperthermia in Canada: characteristics of index anesthetics in 129 malignant hyperthermia susceptible probands. Anesth Analg. 2014;118(2):381–7.

    Article  CAS  PubMed  Google Scholar 

  137. Rosenberg H, Davis M, James D, Pollock N, Stowell K. Malignant hyperthermia. Orphanet J Rare Dis. 2007;2:21.

    Article  PubMed  PubMed Central  Google Scholar 

  138. Bachand M, Vachon N, Boisvert M, Mayer FM, Chartrand D. Clinical reassessment of malignant hyperthermia in Abitibi-Temiscamingue. Can J Anaesth. 1997;44(7):696–701.

    Article  CAS  PubMed  Google Scholar 

  139. Ording H. Incidence of malignant hyperthermia in Denmark. Anesth Analg. 1985;64(7):700–4.

    CAS  PubMed  Google Scholar 

  140. Brady JESM, Sun LSMD, Rosenberg HMD, Li GMDD. Prevalence of malignant hyperthermia due to anesthesia in New York state, 2001–2005. Anesth Analg. 2009;109(4):1162–6.

    Article  PubMed  Google Scholar 

  141. Litman RS, Rosenberg H. Malignant hyperthermia: update on susceptibility testing. JAMA. 2005;293(23):2918–24.

    Article  CAS  PubMed  Google Scholar 

  142. Litman RSDO, Rosenberg HMD. Malignant hyperthermia-associated diseases: state of the art uncertainty. Anesth Analg. 2009;109(4):1004–5.

    Article  PubMed  Google Scholar 

  143. Amburgey K, Bailey A, Hwang JH, Tarnopolsky MA, Bonnemann CG, Medne L, et al. Genotype-phenotype correlations in recessive RYR1-related myopathies. Orphanet J Rare Dis. 2013;8:117.

    Article  PubMed  PubMed Central  Google Scholar 

  144. Brandom BW, Bina S, Wong CA, Wallace T, Visoiu M, Isackson PJ, et al. Ryanodine receptor type 1 gene variants in the malignant hyperthermia-susceptible population of the United States. Anesth Analg. 2013;116(5):1078–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  145. Gillies RL, Bjorksten AR, Du Sart D, Hockey BM. Analysis of the entire ryanodine receptor type 1 and alpha 1 subunit of the dihydropyridine receptor (CACNA1S) coding regions for variants associated with malignant hyperthermia in Australian families. Anaesth Intensive Care. 2015;43(2):157–66.

    Article  CAS  PubMed  Google Scholar 

  146. Gomez AC, Holford TW, Yamaguchi N. Malignant hyperthermia-associated mutations in the S2-S3 cytoplasmic loop of type 1 ryanodine receptor calcium channel impair calcium-dependent inactivation. Am J Physiol Cell Physiol. 2016;311(5):C749–c57.

    Article  PubMed  PubMed Central  Google Scholar 

  147. Gonsalves SG, Ng D, Johnston JJ, Teer JK, Stenson PD, Cooper DN, et al. Using exome data to identify malignant hyperthermia susceptibility mutations. Anesthesiology. 2013;119(5):1043–53.

    Article  CAS  PubMed  Google Scholar 

  148. Haraki T, Yasuda T, Mukaida K, Migita T, Hamada H, Kawamoto M. Mutated p.4894 RyR1 function related to malignant hyperthermia and congenital neuromuscular disease with uniform type 1 fiber (CNMDU1). Anesth Analg. 2011;113(6):1461–7.

    Article  PubMed  Google Scholar 

  149. Ibarra Moreno CA, Hu S, Kraeva N, Schuster F, Johannsen S, Rueffert H, et al. An assessment of penetrance and clinical expression of malignant hyperthermia in individuals carrying diagnostic ryanodine receptor 1 gene mutations. Anesthesiology. 2019;131(5):983–91.

    Article  CAS  PubMed  Google Scholar 

  150. Rosenberg H, Pollock N, Schiemann A, Bulger T, Stowell K. Malignant hyperthermia: a review. Orphanet J Rare Dis. 2015;10:93.

    Article  PubMed  PubMed Central  Google Scholar 

  151. Klingler WMD, Rueffert HMD, Lehmann-Horn FMD, Girard TMD, Hopkins PMMD. Core myopathies and risk of malignant hyperthermia. Anesth Analg. 2009;109(4):1167–73.

    Article  PubMed  Google Scholar 

  152. Alkhunaizi E, Shuster S, Shannon P, Siu VM, Darilek S, Mohila CA, et al. Homozygous/compound heterozygote RYR1 gene variants: expanding the clinical spectrum. Am J Med Genet A. 2019;179(3):386–96.

    Article  CAS  PubMed  Google Scholar 

  153. Bamaga AK, Riazi S, Amburgey K, Ong S, Halliday W, Diamandis P, et al. Neuromuscular conditions associated with malignant hyperthermia in paediatric patients: a 25-year retrospective study. Neuromuscul Disord: NMD. 2016;26(3):201–6.

    Article  PubMed  Google Scholar 

  154. Brislin RP, Theroux MC. Core myopathies and malignant hyperthermia susceptibility: a review. Paediatr Anaesth. 2013;23(9):834–41.

    Article  PubMed  Google Scholar 

  155. De Wel B, Claeys KG. Malignant hyperthermia: still an issue for neuromuscular diseases? Curr Opin Neurol. 2018;31(5):628–34.

    Article  PubMed  Google Scholar 

  156. Hedenmalm K, Granberg AG, Dahl ML. Statin-induced muscle toxicity and susceptibility to malignant hyperthermia and other muscle diseases: a population-based case-control study including 1st and 2nd degree relatives. Eur J Clin Pharmacol. 2015;71(1):117–24.

    Article  CAS  PubMed  Google Scholar 

  157. Nelson P, Litman RS. Malignant hyperthermia in children: an analysis of the North American malignant hyperthermia registry. Anesth Analg. 2014;118(2):369–74.

    Article  PubMed  Google Scholar 

  158. Salazar JH, Yang J, Shen L, Abdullah F, Kim TW. Pediatric malignant hyperthermia: risk factors, morbidity, and mortality identified from the Nationwide Inpatient Sample and Kids’ Inpatient Database. Paediatr Anaesth. 2014;24(12):1212–6.

    Article  PubMed  Google Scholar 

  159. Broman M, Heinecke K, Islander G, Schuster F, Glahn K, Bodelsson M, et al. Screening of the ryanodine 1 gene for malignant hyperthermia causative mutations by high resolution melt curve analysis. Anesth Analg. 2011;113(5):1120–8.

    Article  CAS  PubMed  Google Scholar 

  160. JSA guideline for the management of malignant hyperthermia crisis 2016. J Anesth. 2017;31(2):307–17.

    Google Scholar 

  161. Glahn KP, Ellis FR, Halsall PJ, Müller CR, Snoeck MM, Urwyler A, et al. Recognizing and managing a malignant hyperthermia crisis: guidelines from the European Malignant Hyperthermia Group. Br J Anaesth. 2010;105(4):417–20.

    Article  CAS  PubMed  Google Scholar 

  162. Litman RS, Smith VI, Larach MG, Mayes L, Shukry M, Theroux MC, et al. Consensus statement of the malignant hyperthermia association of the United States on unresolved clinical questions concerning the management of patients with malignant hyperthermia. Anesth Analg. 2019;128(4):652–9.

    Article  PubMed  Google Scholar 

  163. Amano T, Fukami T, Ogiso T, Hirose D, Jones JP, Taniguchi T, et al. Identification of enzymes responsible for dantrolene metabolism in the human liver: a clue to uncover the cause of liver injury. Biochem Pharmacol. 2018;151:69–78.

    Article  CAS  PubMed  Google Scholar 

  164. Brandom BW, Larach MG, Chen MS, Young MC. Complications associated with the administration of dantrolene 1987 to 2006: a report from the North American Malignant Hyperthermia Registry of the Malignant Hyperthermia Association of the United States. Anesth Analg. 2011;112(5):1115–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  165. Kaku DA, Lowenstein DH. Emergence of recreational drug abuse as a major risk factor for stroke in young adults. Ann Intern Med. 1990;113(11):821–7.

    Article  CAS  PubMed  Google Scholar 

  166. Devgun J, Rasin A, Kim T, Mycyk M, Bryant S, Wahl M, et al. An outbreak of severe coagulopathy from synthetic cannabinoids tainted with long-acting anticoagulant rodenticides. Clin Toxicol (Philadelphia, Pa). 2019:1–8.

    Google Scholar 

  167. Courts J, Maskill V, Gray A, Glue P. Signs and symptoms associated with synthetic cannabinoid toxicity: systematic review. Australas Psychiatry. 2016;24(6):598–601.

    Article  PubMed  Google Scholar 

  168. Freeman MJ, Rose DZ, Myers MA, Gooch CL, Bozeman AC, Burgin WS. Ischemic stroke after use of the synthetic marijuana "spice". Neurology. 2013;81(24):2090–3.

    Article  PubMed  PubMed Central  Google Scholar 

  169. Tait RJ, Caldicott D, Mountain D, Hill SL, Lenton S. A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clin Toxicol (Philadelphia, Pa). 2016;54(1):1–13.

    Google Scholar 

  170. Piano MR. Cannabis smoking and cardiovascular health: It’s complicated. Clin Pharmacol Ther. 2017;102(2):191–3.

    Article  CAS  PubMed  Google Scholar 

  171. Wolff V, Jouanjus E. Strokes are possible complications of cannabinoids use. Epilepsy Behav: E&B. 2017;70(Pt B):355–63.

    Google Scholar 

  172. Wolff V, Armspach JP, Beaujeux R, Manisor M, Rouyer O, Lauer V, et al. High frequency of intracranial arterial stenosis and cannabis use in ischaemic stroke in the young. Cerebrovasc Dis (Basel, Switzerland). 2014;37(6):438–43.

    Google Scholar 

  173. Warner EA. Cocaine abuse. Ann Intern Med. 1993;119(3):226–35.

    Article  CAS  PubMed  Google Scholar 

  174. Van Dyke C, Barash PG, Jatlow P, Byck R. Cocaine: plasma concentrations after intranasal application in man. Science. 1976;191(4229):859–61.

    Article  PubMed  Google Scholar 

  175. Jenkins AJ, Keenan RM, Henningfield JE, Cone EJ. Correlation between pharmacological effects and plasma cocaine concentrations after smoked administration. J Anal Toxicol. 2002;26(7):382–92.

    Article  CAS  PubMed  Google Scholar 

  176. Fleming JA, Byck R, Barash PG. Pharmacology and therapeutic applications of cocaine. Anesthesiology. 1990;73(3):518–31.

    Article  CAS  PubMed  Google Scholar 

  177. Dean RA, Christian CD, Sample RH, Bosron WF. Human liver cocaine esterases: ethanol-mediated formation of ethylcocaine. FASEB J. 1991;5(12):2735–9.

    Article  CAS  PubMed  Google Scholar 

  178. Brust JC, Richter RW. Stroke associated with cocaine abuse--? N Y State J Med. 1977;77(9):1473–5.

    CAS  PubMed  Google Scholar 

  179. Westover AN, McBride S, Haley RW. Stroke in young adults who abuse amphetamines or cocaine: a population-based study of hospitalized patients. Arch Gen Psychiatry. 2007;64(4):495–502.

    Article  PubMed  Google Scholar 

  180. Sloan MAM, Kittner SJMM, Feeser BRMM, Gardner JM, Epstein A, Wozniak MAMDP, et al. Illicit drug-associated ischemic stroke in the Baltimore-Washington Young Stroke Study. Neurology. 1998;50(6):1688–93.

    Article  CAS  PubMed  Google Scholar 

  181. Kaufman MJ, Levin JM, Ross MH, Lange N, Rose SL, Kukes TJ, et al. Cocaine-induced cerebral vasoconstriction detected in humans with magnetic resonance angiography. JAMA. 1998;279(5):376–80.

    Article  CAS  PubMed  Google Scholar 

  182. He GQ, Zhang A, Altura BT, Altura BM. Cocaine-induced cerebrovasospasm and its possible mechanism of action. J Pharmacol Exp Ther. 1994;268(3):1532–9.

    CAS  PubMed  Google Scholar 

  183. Du C, Yu M, Volkow ND, Koretsky AP, Fowler JS, Benveniste H. Cocaine increases the intracellular calcium concentration in brain independently of its cerebrovascular effects. J Neurosci. 2006;26(45):11522–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  184. Brown E, Prager J, Lee HY, Ramsey RG. CNS complications of cocaine abuse: prevalence, pathophysiology, and neuroradiology. AJR: Am J Roentgenol. 1992;159(1):137–47.

    Google Scholar 

  185. Büttner A. Neuropathological alterations in cocaine abuse. Curr Med Chem. 2012;19(33):5597–600.

    Article  PubMed  Google Scholar 

  186. Jacobs IG, Roszler MH, Kelly JK, Klein MA, Kling GA. Cocaine abuse: neurovascular complications. Radiology. 1989;170(1 Pt 1):223–7.

    Article  CAS  PubMed  Google Scholar 

  187. Lowenstein DH, Massa SM, Rowbotham MC, Collins SD, McKinney HE, Simon RP. Acute neurologic and psychiatric complications associated with cocaine abuse. Am J Med. 1987;83(5):841–6.

    Article  CAS  PubMed  Google Scholar 

  188. Levine SR, Brust JC, Futrell N, Ho KL, Blake D, Millikan CH, et al. Cerebrovascular complications of the use of the “crack” form of alkaloidal cocaine. N Engl J Med. 1990;323(11):699–704.

    Article  CAS  PubMed  Google Scholar 

  189. Levine SR, Brust JC, Futrell N, Brass LM, Blake D, Fayad P, et al. A comparative study of the cerebrovascular complications of cocaine: alkaloidal versus hydrochloride--a review. Neurology. 1991;41(8):1173–7.

    Article  CAS  PubMed  Google Scholar 

  190. Mody CK, Miller BL, McIntyre HB, Cobb SK, Goldberg MA. Neurologic complications of cocaine abuse. Neurology. 1988;38(8):1189–93.

    Article  CAS  PubMed  Google Scholar 

  191. Konzen JP, Levine SR, Garcia JH. Vasospasm and thrombus formation as possible mechanisms of stroke related to alkaloidal cocaine. Stroke. 1995;26(6):1114–8.

    Article  CAS  PubMed  Google Scholar 

  192. Togna G, Tempesta E, Togna AR, Dolci N, Cebo B, Caprino L. Platelet responsiveness and biosynthesis of thromboxane and prostacyclin in response to in vitro cocaine treatment. Haemostasis. 1985;15(2):100–7.

    CAS  PubMed  Google Scholar 

  193. Klonoff DC, Andrews BT, Obana WG. Stroke associated with cocaine use. Arch Neurol. 1989;46(9):989–93.

    Article  CAS  PubMed  Google Scholar 

  194. Kaye BR, Fainstat M. Cerebral vasculitis associated with cocaine abuse. JAMA. 1987;258(15):2104–6.

    Article  CAS  PubMed  Google Scholar 

  195. Krendel DA, Ditter SM, Frankel MR, Ross WK. Biopsy-proven cerebral vasculitis associated with cocaine abuse. Neurology. 1990;40(7):1092–4.

    Article  CAS  PubMed  Google Scholar 

  196. Sloan MA, Mattioni TA. Concurrent myocardial and cerebral infarctions after intranasal cocaine use. Stroke. 1992;23(3):427–30.

    Article  CAS  PubMed  Google Scholar 

  197. Sauer CM. Recurrent embolic stroke and cocaine-related cardiomyopathy. Stroke. 1991;22(9):1203–5.

    Article  CAS  PubMed  Google Scholar 

  198. Kibayashi K, Mastri AR, Hirsch CS. Cocaine induced intracerebral hemorrhage: analysis of predisposing factors and mechanisms causing hemorrhagic strokes. Hum Pathol. 1995;26(6):659–63.

    Article  CAS  PubMed  Google Scholar 

  199. Kelley PA, Sharkey J, Philip R, Ritchie IM. Acute cocaine alters cerebrovascular autoregulation in the rat neocortex. Brain Res Bull. 1993;31(5):581–5.

    Article  CAS  PubMed  Google Scholar 

  200. Treadwell SD, Robinson TG. Cocaine use and stroke. Postgrad Med J. 2007;83(980):389–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  201. Martin-Schild SMDP, Albright KCDOMPH, Misra VMD, Philip MMD, Barreto ADMD, Hallevi HMD, et al. Intravenous tissue plasminogen activator in patients with cocaine-associated acute ischemic stroke. Stroke. 2009;40(11):3635–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  202. Ramoska E, Sacchetti AD. Propranolol-induced hypertension in treatment of cocaine intoxication. Ann Emerg Med. 1985;14(11):1112–3.

    Article  CAS  PubMed  Google Scholar 

  203. Catravas JD, Waters IW. Acute cocaine intoxication in the conscious dog: studies on the mechanism of lethality. J Pharmacol Exp Ther. 1981;217(2):350–6.

    CAS  PubMed  Google Scholar 

  204. Richards JR, Garber D, Laurin EG, Albertson TE, Derlet RW, Amsterdam EA, et al. Treatment of cocaine cardiovascular toxicity: a systematic review. Clin Toxicol (Philadelphia, Pa). 2016;54(5):345–64.

    Google Scholar 

  205. O’Connor AD, Rusyniak DE, Bruno A. Cerebrovascular and cardiovascular complications of alcohol and sympathomimetic drug abuse. Med Clin N Am. 2005;89(6):1343–58.

    Article  PubMed  Google Scholar 

  206. Ho EL, Josephson SA, Lee HS, Smith WS. Cerebrovascular complications of methamphetamine abuse. Neurocrit Care. 2009;10(3):295–305.

    Article  PubMed  Google Scholar 

  207. Edwards KR. Hemorrhagic complications of cerebral arteritis. Arch Neurol. 1977;34(9):549–52.

    Article  CAS  PubMed  Google Scholar 

  208. Selmi F, Davies KG, Sharma RR, Neal JW. Intracerebral haemorrhage due to amphetamine abuse: report of two cases with underlying arteriovenous malformations. Br J Neurosurg. 1995;9(1):93–6.

    Article  CAS  PubMed  Google Scholar 

  209. Harrington H, Heller HA, Dawson D, Caplan L, Rumbaugh C. Intracerebral hemorrhage and oral amphetamine. Arch Neurol. 1983;40(8):503–7.

    Article  CAS  PubMed  Google Scholar 

  210. Hondebrink L, Nugteren-van Lonkhuyzen JJ, Rietjens SJ, Brunt TM, Venhuis B, Soerdjbalie-Maikoe V, et al. Fatalities, cerebral hemorrhage, and severe cardiovascular toxicity after exposure to the new psychoactive substance 4-fluoroamphetamine: a prospective cohort study. Ann Emerg Med. 2018;71(3):294–305.

    Article  PubMed  Google Scholar 

  211. Le Roux G, Bruneau C, Lelièvre B, Bretaudeau Deguigne M, Turcant A, Harry P, et al. Recreational phenethylamine poisonings reported to a French poison control center. Drug Alcohol Depend. 2015;154:46–53.

    Article  PubMed  Google Scholar 

  212. McGee SMMD, McGee DNPB, McGee MBMD. Spontaneous intracerebral hemorrhage related to methamphetamine abuse: autopsy findings and clinical correlation. Am J Forensic Med Pathol. 2004;25(4):334–7.

    Article  PubMed  Google Scholar 

  213. Lappin JM, Darke S, Farrell M. Stroke and methamphetamine use in young adults: a review. J Neurol Neurosurg Psychiatry. 2017;88(12):1079–91.

    Article  PubMed  Google Scholar 

  214. Auer J, Berent R, Weber T, Lassnig E, Eber B. Subarachnoid haemorrhage with “Ecstasy” abuse in a young adult. Neurol Sci. 2002;23(4):199–201.

    Article  CAS  PubMed  Google Scholar 

  215. McEvoy AW, Kitchen ND, Thomas DG. Intracerebral haemorrhage and drug abuse in young adults. Br J Neurosurg. 2000;14(5):449–54.

    Article  CAS  PubMed  Google Scholar 

  216. De Silva DA, Wong MC, Lee MP, Chen CL-H, Chang HM. Amphetamine-associated ischemic stroke: clinical presentation and proposed pathogenesis. J Stroke Cerebrovasc Dis. 2007;16(4):185–6.

    Article  PubMed  Google Scholar 

  217. Manchanda S, Connolly MJ. Cerebral infarction in association with Ecstasy abuse. Postgrad Med J. 1993;69(817):874–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  218. McDonald ES, Lane JI. Dietary supplements and stroke. Mayo Clin Proc. 2005;80(3):315.

    Article  PubMed  Google Scholar 

  219. Chen C, Biller J, Willing SJ, Lopez AM. Ischemic stroke after using over the counter products containing ephedra. J Neurol Sci. 2004;217(1):55–60.

    Article  PubMed  Google Scholar 

  220. Yoon BWMDP, Bae HJMDP, Hong KSMDP, Lee SMP, Park BJMDP, Yu KHMDP, et al. Phenylpropanolamine contained in cold remedies and risk of hemorrhagic stroke. Neurology. 2007;68(2):146–9.

    Article  CAS  PubMed  Google Scholar 

  221. Kernan WN, Viscoli CM, Brass LM, Broderick JP, Brott T, Feldmann E, et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med. 2000;343(25):1826–32.

    Article  CAS  PubMed  Google Scholar 

  222. Cantu C, Arauz A, Murillo-Bonilla LM, Lopez M, Barinagarrementeria F. Stroke associated with sympathomimetics contained in over-the-counter cough and cold drugs. Stroke. 2003;34(7):1667–72.

    Article  CAS  PubMed  Google Scholar 

  223. Wills B, Theeler BJ, Ney JP. Drug- and toxin-associated seizures. In: Dobbs MR, editor. Clinical neurotoxicology: syndromes, substances, environments. Philadelphia: Saunders Elsevier; 2009. p. 131–50.

    Chapter  Google Scholar 

  224. McGarvey CK, Rusyniak DE. Neurotoxicology. In: Biller J, editor. Practical neurology. 3rd ed. Philadelphia: Lippincott, Williams, & Wilkins; 2009. p. 745–63.

    Google Scholar 

  225. Thundiyil JG, Kearney TE, Olson KR. Evolving epidemiology of drug-induced seizures reported to a Poison Control Center System. J Med Toxicol. 2007;3(1):15–9.

    Article  PubMed  PubMed Central  Google Scholar 

  226. Cock H. Drug-induced status epilepticus. Epilepsy Behav: E&B. 2015:76–82.

    Google Scholar 

  227. Sutter R, Ruegg S, Tschudin-Sutter S. Seizures as adverse events of antibiotic drugs; a systematic review. Neurology. 2015;85(15):1332–41.

    Article  CAS  PubMed  Google Scholar 

  228. Druschky K, Bleich S, Grohmann R, Engel R, Neyazi A, Stubner S, et al. Seizure rates under treatment with antipsychotic drugs: data from the AMSP project. World J Biol Psychiatry. 2019;20(9):732–41.

    Article  PubMed  Google Scholar 

  229. Riley AL, Nelson KH, To P, Lopez-Arnau R, Xu P, Wang D, et al. Abuse potential and toxicity of the synthetic cathinones (i.e., “Bath salts”). Neurosci Biobehav Rev. 2020;110:150–73.

    Google Scholar 

  230. Frommer DA, Kulig KW, Marx JA, Rumack B. Tricyclic antidepressant overdose. A review. JAMA. 1987;257(4):521–6.

    Article  CAS  PubMed  Google Scholar 

  231. Boehnert MT, Lovejoy FH Jr. Value of the QRS duration versus the serum drug level in predicting seizures and ventricular arrhythmias after an acute overdose of tricyclic antidepressants. N Engl J Med. 1985;313(8):474–9.

    Article  CAS  PubMed  Google Scholar 

  232. Hulten BA, Adams R, Askenasi R, Dallos V, Dawling S, Volans G, et al. Predicting severity of tricyclic antidepressant overdose. J Toxicol Clin Toxicol. 1992;30(2):161–70.

    Article  CAS  PubMed  Google Scholar 

  233. Brust JCM. Seizures and substance abuse: treatment considerations. Neurology. 2006;67(12 Suppl 4):S45–8.

    Article  PubMed  Google Scholar 

  234. Kofler M, Arturo Leis A. Prolonged seizure activity after baclofen withdrawal. Neurology. 1992;42(3 Pt 1):697–8.

    CAS  PubMed  Google Scholar 

  235. Boison D. Methylxanthines, seizures, and excitotoxicity. Handb Exp Pharmacol. 2011;200:251–66.

    Article  CAS  Google Scholar 

  236. Chen HY, Albertson TE, Olsen KR. Treatment of drug-induced seizures. Br J Clin Pharmacol. 2016;81(3):412–9.

    Article  CAS  PubMed  Google Scholar 

  237. D'Onofrio G, Rathlev NK, Ulrich AS, Fish SS, Freedland ES. Lorazepam for the prevention of recurrent seizures related to alcohol. N Engl J Med. 1999;340(12):915–9.

    Article  CAS  PubMed  Google Scholar 

  238. Rathlev NK, D’Onofrio G, Fish SS, Harrison PM, Bernstein E, Hossack RW, et al. The lack of efficacy of phenytoin in the prevention of recurrent alcohol-related seizures. Ann Emerg Med. 1994;23(3):513–8.

    Article  CAS  PubMed  Google Scholar 

  239. Starr P, Klein-Schwartz W, Spiller H, Kern P, Ekleberry SE, Kunkel S. Incidence and onset of delayed seizures after overdoses of extended-release bupropion. Am J Emerg Med. 2009;27(8):911–5.

    Article  PubMed  Google Scholar 

  240. Paloucek FP, Rodvold KA. Evaluation of theophylline overdoses and toxicities. Ann Emerg Med. 1988;17(2):135–44.

    Article  CAS  PubMed  Google Scholar 

  241. Zwillich CW, Sutton FD, Neff TA, Cohn WM, Matthay RA, Weinberger MM. Theophylline-induced seizures in adults. Correlation with serum concentrations. Ann Intern Med. 1975;82(6):784–7.

    Article  CAS  PubMed  Google Scholar 

  242. Wills B, Erickson T. Drug- and toxin-associated seizures. Med Clin N Am. 2005;89(6):1297–321.

    Article  CAS  PubMed  Google Scholar 

  243. Lee T, Warrick BJ, Sarangarm P, Alunday RL, Bussmann S, Smolinske SC, et al. Levetiracetam in toxic seizures. Clin Toxicol (Philadelphia, Pa). 2018;56(3):175–81.

    Google Scholar 

  244. Juurlink DN, Gosselin S, Kielstein JT, Ghannoum M, Lavergne V, Nolin TD, et al. Extracorporeal treatment for salicylate poisoning: systematic review and recommendations from the EXTRIP workgroup. Ann Emerg Med. 2015;66(2):165–81.

    Article  PubMed  Google Scholar 

  245. Ghannoum M, Wiegand TJ, Liu KD, Calello DP, Godin M, Lavergne V, et al. Extracorporeal treatment for theophylline poisoning: systematic review and recommendations from the EXTRIP workgroup. Clin Toxicol (Philadelphia, Pa). 2015;53(4):215–29.

    Google Scholar 

  246. Decker BS, Goldfarb DS, Dargan PI, Friesen M, Gosselin S, Hoffman RS, et al. Extracorporeal treatment for lithium poisoning: systematic review and recommendations from the EXTRIP workgroup. Clin J Am Soc Nephrol: CJASN. 2015;10(5):875–87.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  247. Lawrence DT, Kirk MA. Chemical terrorism attacks: update on antidotes. Emerg Med Clin North Am. 2007;25(2):567–95; abstract xi.

    Google Scholar 

  248. Black RE, Gunn RA. Hypersensitivity reactions associated with botulinal antitoxin. Am J Med. 1980;69(4):567–70.

    Article  CAS  PubMed  Google Scholar 

  249. Nelson BK. Snake envenomation. Incidence, clinical presentation and management. Med Toxicol Adverse Drug Exp. 1989;4(1):17–31.

    CAS  PubMed  Google Scholar 

  250. Lawrence D, McLinskey N, Huff S, Holstege CP. Toxin-induced neurologic emergencies. In: Dobbs MR, editor. Clinical neurotoxicology: syndromes, substances, environments. Philadelphia: Saunders Elsevier; 2009. p. 30–46.

    Chapter  Google Scholar 

  251. Chamberlain JM, Klein BL. A comprehensive review of naloxone for the emergency physician. Am J Emerg Med. 1994;12(6):650–60.

    Article  CAS  PubMed  Google Scholar 

  252. Clarke SFJ, Dargan PI, Jones AL. Naloxone in opioid poisoning: walking the tightrope. Emerg Med J. 2005;22(9):612–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  253. Watkins JW, Schwarz ES, Arroyo-Plasencia AM, Mullins ME, Toxicology Investigators Consortium Investigators. Toxicology the use of physostigmine by toxicologists in anticholinergic toxicity. J Med Toxicol. 2015;11(2):179–84.

    Article  CAS  PubMed  Google Scholar 

  254. Arens AM, Shah K, Al-Abri S, Olson KR, Kearney T. Safety and effectiveness of physostigmine: a 10-year retrospective review. Clin Toxicol (Philadelphia, Pa). 2018;56(2):101–7.

    Google Scholar 

  255. Boley SP, Stellpflug SJ. A comparison of resource utilization in the management of anticholinergic delirium between physostigmine and nonantidote therapy. Ann Pharmacother. 2019;53(10):1026–32.

    Article  CAS  PubMed  Google Scholar 

  256. Boley SP, Olives TD, Bangh SA, Fahrner S, Cole JB. Physostigmine is superior to non-antidote therapy in the management of antimuscarinic delirium: a prospective study from a regional poison center. Clin Toxicol (Philadelphia, Pa). 2019;57(1):50–5.

    Google Scholar 

  257. Burns MJ, Linden CH, Graudins A, Brown RM, Fletcher KE. A comparison of physostigmine and benzodiazepines for the treatment of anticholinergic poisoning. Ann Emerg Med. 2000;35(4):374–81.

    Article  CAS  PubMed  Google Scholar 

  258. Dawson AH, Buckley NA. Pharmacological management of anticholinergic delirium - theory, evidence and practice. Br J Clin Pharmacol. 2016;81(3):516–24.

    Article  CAS  PubMed  Google Scholar 

  259. Nilsson E. Physostigmine treatment in various drug-induced intoxications. Ann Clin Res. 1982;14(4):165–72.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neurology and Emergency Medicine, Indiana University School of Medicine, Indianapolis, IN, USA

    Laura M. Tormoehlen

Authors
  1. Laura M. Tormoehlen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Laura M. Tormoehlen .

Editor information

Editors and Affiliations

  1. The John and Nancy Nelson Professor of Neurology, Indiana University School of Medicine, Indianapolis, IN, USA

    Karen L. Roos

Rights and permissions

Reprints and permissions

Copyright information

© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Tormoehlen, L.M. (2021). Neurotoxicology Emergencies. In: Roos, K.L. (eds) Emergency Neurology. Springer, Cham. https://doi.org/10.1007/978-3-030-75778-6_18

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-75778-6_18

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-75777-9

  • Online ISBN: 978-3-030-75778-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation